BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

British Journal of Ophthalmology 2006;90:5-6; doi:10.1136/bjo.2005.079889
Copyright © 2006 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stewart, J M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stewart, J M
Topic Collections
Right arrowRelated Article

EDITORIAL

Age related macular degeneration

Thrombospondin in the eye

J M Stewart

Correspondence to:
Correspondence to:
Dr Jay M Stewart University of California
San Francisco, Department of Ophthalmology, 10 Koret Way, K301, San Francisco, CA 94143-0730, USA; ne62@yahoo.com


A regulator of angiogenesis

Keywords: thrombospondin; age related macular degeneration; extracellular matrix; Bruch’s membrane

The first 150 words of the full text of this article appear below.

Research into the pathophysiology of age related macular degeneration (AMD) has advanced at a rapid rate in recent years. To see the pace of progress, one need only pick up any issue of a major ophthalmic journal or attend a poster session at an ophthalmic society meeting. Efforts are under way to learn more about the ageing of Bruch’s membrane, drusen formation, and angiogenesis in choroidal neovascularisation (CNV). And it’s beginning to pay off: our understanding of these mechanisms has led to some promising new treatments, particularly in the area of angiogenesis.

In the case of CNV, much of the focus lately has been on pro-angiogenic proteins such as vascular endothelial growth factor (VEGF). Treatment strategies that target pathologically elevated levels of VEGF are easy to understand: they try to block or reduce a known stimulus for the growth of CNV. Some early successes have been . . . [Full text of this article]


Related Article

Impaired expression of thrombospondin-1 in eyes with age related macular degeneration
K Uno, I A Bhutto, D S McLeod, C Merges, and G A Lutty
Br. J. Ophthalmol. 2006 90: 48-54. [Abstract] [Full Text] [PDF]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd.